Kuangli Bio-Tech Holdings Co., Ltd. Statistics
Kuangli Bio-Tech Holdings Co., Ltd. (6431) Stock Statistics & Valuation Metrics
Total Valuation
Kuangli Bio-Tech Holdings Co., Ltd. has a market cap or net worth of TWD 1.45B. The enterprise value is TWD 2.05B.
- Market Cap
- TWD 1.45B
- Enterprise Value
- TWD 2.05B
Share Statistics
Kuangli Bio-Tech Holdings Co., Ltd. has 97,398,834 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 97,398,834
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Kuangli Bio-Tech Holdings Co., Ltd.’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -14.72%.
- Return on Equity (ROE)
- -0.33
- Return on Assets (ROA)
- -0.16
- Return on Invested Capital (ROIC)
- -14.72%
- Return on Capital Employed (ROCE)
- -0.19
- Revenue Per Employee
- 2.09M
- Profits Per Employee
- -1.07M
- Employee Count
- 180
- Asset Turnover
- 0.32
- Inventory Turnover
- 6.59
Valuation Ratios
The current PE Ratio of Kuangli Bio-Tech Holdings Co., Ltd. is -7.35. Kuangli Bio-Tech Holdings Co., Ltd.’s PEG ratio is -0.51.
- PE Ratio
- -7.35
- PS Ratio
- 3.90
- PB Ratio
- 2.83
- Price to FCF
- -6.51
- Price to Operating Cash Flow
- -7.42
- PEG Ratio
- -0.51
Income Statement
In the last 12 months, Kuangli Bio-Tech Holdings Co., Ltd. had revenue of 377.03M and earned -193.04M in profits. Earnings per share was -2.07.
- Revenue
- 377.03M
- Gross Profit
- 70.41M
- Operating Income
- -157.48M
- Pretax Income
- -193.04M
- Net Income
- -193.04M
- EBITDA
- -92.46M
- Earnings Per Share (EPS)
- -2.07
Cash Flow
In the last 12 months, operating cash flow was -192.61M and capital expenditures -25.15M, giving a free cash flow of -217.76M billion.
- Operating Cash Flow
- -192.61M
- Free Cash Flow
- -217.76M
- Free Cash Flow per Share
- -2.22
Dividends & Yields
Kuangli Bio-Tech Holdings Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -15.37%
- Earnings Yield
- -13.33%
Stock Price Statistics
- Beta
- 0.26
- 52-Week Price Change
- -9.17%
- 50-Day Moving Average
- 17.16
- 200-Day Moving Average
- 20.02
- Relative Strength Index (RSI)
- 36.74
- Average Volume (3m)
- 92.12K
Important Dates
Kuangli Bio-Tech Holdings Co., Ltd. upcoming earnings date is Nov 17, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 26, 2026
- Next Earnings Date
- Nov 17, 2026
- Ex-Dividend Date
- ―
Financial Position
Kuangli Bio-Tech Holdings Co., Ltd. as a current ratio of 1.36, with Debt / Equity ratio of 84.40%
- Current Ratio
- 1.36
- Quick Ratio
- 1.22
- Debt to Market Cap
- 0.08
- Net Debt to EBITDA
- -3.01
- Interest Coverage Ratio
- -11.49
Taxes
In the past 12 months, Kuangli Bio-Tech Holdings Co., Ltd. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Kuangli Bio-Tech Holdings Co., Ltd. EV to EBITDA ratio is -21.66, with an EV/FCF ratio of -7.83.
- EV to Sales
- 4.69
- EV to EBITDA
- -21.66
- EV to Free Cash Flow
- -7.83
- EV to Operating Cash Flow
- -8.85
Balance Sheet
Kuangli Bio-Tech Holdings Co., Ltd. has TWD 221.67M in cash and marketable securities with TWD 509.04M in debt, giving a net cash position of -TWD 287.37M billion.
- Cash & Marketable Securities
- TWD 221.67M
- Total Debt
- TWD 509.04M
- Net Cash
- -TWD 287.37M
- Net Cash Per Share
- -TWD 2.95
- Tangible Book Value Per Share
- TWD 2.72
Margins
Gross margin is 20.96%, with operating margin of -44.60%, and net profit margin of -52.44%.
- Gross Margin
- 20.96%
- Operating Margin
- -44.60%
- Pretax Margin
- -50.23%
- Net Profit Margin
- -52.44%
- EBITDA Margin
- -21.66%
- EBIT Margin
- -45.41%
Analyst Forecast
The average price target for Kuangli Bio-Tech Holdings Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -14.57%
- EPS Growth Forecast
- 13.16%
